Загрузка...
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
The introduction of vedolizumab, a lymphocyte adhesion inhibitor, has expanded the relatively limited therapeutic armamentarium available for Crohn’s disease and ulcerative colitis. Despite its effectiveness, both primary nonresponse and secondary loss of response to vedolizumab do occur, as is obse...
Сохранить в:
| Опубликовано в: : | Therap Adv Gastroenterol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5949937/ https://ncbi.nlm.nih.gov/pubmed/29774052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284818772786 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|